Mitsubishi Tanabe Ph (MTZXF) 15.0500 $MTZXF
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Global Market Study on Diabetic Nephropathy 2014-2020
M2 - Wed Jul 08, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq485/global_market) has announced the addition of the "Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020" report to their offering. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. Companies Mentioned - AbbVie, Inc. - Abbott Laboratories - Bayer AG - Eli Lilly and Company - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis AG - Pfizer, Inc. - Reata Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/jb...bal_market
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 66.45 (+1.90)
Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:24AM CDT
Product Pipeline Review - 2014
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 5.64 (+0.25), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CTIC: 1.91 (+0.03), CNCE: 15.71 (+0.27), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), CCXI: 8.60 (+0.19), ICPT: 247.71 (+4.45), ABBV: 69.23 (+1.26)
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 388.23 (-11.06), ACOR: 34.07 (+0.65), GSK: 42.45 (+0.65), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
Neurocrine Biosciences Reports First Quarter 2015 Results
PR Newswire - Thu Apr 30, 6:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.
NBIX: 48.16 (+0.33)
Optic Neuritis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 9:30AM CDT
The report "Optic Neuritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Optic Neuritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/optic-neurit...eport.html .
CUR: 1.69 (-0.01)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.26 (-0.25), FOMX: 11.18 (+0.22), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), DERM: 18.22 (+0.30), ANAC: 84.61 (+1.95), XNCR: 22.60 (+0.13), REGN: 526.01 (+16.98), AQXP: 1.94 (-0.19), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VRX.TO: 294.65 (+11.22), CBPO: 111.03 (+7.77), MRK: 57.95 (+0.57), CCXI: 8.60 (+0.19), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14), NVS: 103.22 (+3.20)
Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets
PR Newswire - Tue Mar 31, 9:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.
NBIX: 48.16 (+0.33)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 388.23 (-11.06), SIAL: 139.36 (+0.04), MRK: 57.95 (+0.57)
Hyperphosphatemia Pipeline Review, H1 2015 - 10 Companies & 16 Drug Profiles
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xr5cx/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - AstraZeneca PLC - Medice Arzneimittel Putter GmbH & Co. KG - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - Panion & Bf Biotech Inc - Sanofi - Spectrum Pharmaceuticals, Inc. - Toray Industries, Inc. - Vifor Pharma AG Drug Profiles - ASP-3325 - colestilan chloride - Fe-SAMMS - fermagate - ferric citrate - JPH-101 - niacinamide - PT-20 - RDX-002 - Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - SPI-014 - sucroferric oxyhydroxide - tenapanor hydrochloride - TRK-390 - VS-501 - VS-505 For more information visit http://www.researchandmarkets.com/research/5x...osphatemia
OPK: 16.55 (-0.01), AZN: 66.45 (+1.90), SPPI: 7.08 (+0.05)
GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 13.77 (+0.12)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 99.53 (+1.13), GTXI: 1.37 (+0.01), ESPR: 90.01 (+1.32), ISIS: 53.50 (+0.42), PFE: 34.36 (+0.50), NEOT: 9.91 (+0.68), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 37.53 (+0.49), PFE: 34.36 (+0.50), ACOR: 34.07 (+0.65)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.36 (+0.50)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 49.93 (+0.74), MDT: 74.37 (+1.28), LXRX: 8.21 (-0.10), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), ECTE: 1.71 (+0.13), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.92 (unch), APRI: 1.76 (+0.01)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 61.38 (-0.75), ITCI: 34.76 (+1.70), BCLI: 3.46 (-0.03), OMER: 17.33 (+0.29), NVS: 103.22 (+3.20)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), MRK: 57.95 (+0.57), CGEN: 6.63 (+0.06), PTN: 0.92 (unch), TEVA: 61.38 (-0.75), NVS: 103.22 (+3.20)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Global Market Study on Diabetic Nephropathy 2014-2020
M2 - Wed Jul 08, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq485/global_market) has announced the addition of the "Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020" report to their offering. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. Companies Mentioned - AbbVie, Inc. - Abbott Laboratories - Bayer AG - Eli Lilly and Company - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis AG - Pfizer, Inc. - Reata Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/jb...bal_market
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 66.45 (+1.90)
Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:24AM CDT
Product Pipeline Review - 2014
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 5.64 (+0.25), GALT: 2.67 (+0.12), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), CTIC: 1.91 (+0.03), CNCE: 15.71 (+0.27), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), CCXI: 8.60 (+0.19), ICPT: 247.71 (+4.45), ABBV: 69.23 (+1.26)
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 388.23 (-11.06), ACOR: 34.07 (+0.65), GSK: 42.45 (+0.65), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01)
Neurocrine Biosciences Reports First Quarter 2015 Results
PR Newswire - Thu Apr 30, 6:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.
NBIX: 48.16 (+0.33)
Optic Neuritis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 22, 9:30AM CDT
The report "Optic Neuritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Optic Neuritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/optic-neurit...eport.html .
CUR: 1.69 (-0.01)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.26 (-0.25), FOMX: 11.18 (+0.22), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), DERM: 18.22 (+0.30), ANAC: 84.61 (+1.95), XNCR: 22.60 (+0.13), REGN: 526.01 (+16.98), AQXP: 1.94 (-0.19), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VRX.TO: 294.65 (+11.22), CBPO: 111.03 (+7.77), MRK: 57.95 (+0.57), CCXI: 8.60 (+0.19), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14), NVS: 103.22 (+3.20)
Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets
PR Newswire - Tue Mar 31, 9:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.
NBIX: 48.16 (+0.33)
Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020
M2 - Fri Mar 27, 7:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dv95g/albumin) has announced the addition of the "Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth. The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter). CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Albumin Market Overview Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 - 2020 Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020 Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020 Chapter 7 Recommendations Chapter 8 Company Profiles - CSL Behring LLC - HiMedia Laboratories - InVitria (Ventria Bioscience) - MedxBio Pte. Ltd. - Mitsubishi Tanabe Pharma - Novozymes A/S - Octapharma AG - RayBiotech, Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/5dv95g/albumin
BIIB: 388.23 (-11.06), SIAL: 139.36 (+0.04), MRK: 57.95 (+0.57)
Hyperphosphatemia Pipeline Review, H1 2015 - 10 Companies & 16 Drug Profiles
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xr5cx/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Astellas Pharma Inc. - AstraZeneca PLC - Medice Arzneimittel Putter GmbH & Co. KG - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - Panion & Bf Biotech Inc - Sanofi - Spectrum Pharmaceuticals, Inc. - Toray Industries, Inc. - Vifor Pharma AG Drug Profiles - ASP-3325 - colestilan chloride - Fe-SAMMS - fermagate - ferric citrate - JPH-101 - niacinamide - PT-20 - RDX-002 - Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - SPI-014 - sucroferric oxyhydroxide - tenapanor hydrochloride - TRK-390 - VS-501 - VS-505 For more information visit http://www.researchandmarkets.com/research/5x...osphatemia
OPK: 16.55 (-0.01), AZN: 66.45 (+1.90), SPPI: 7.08 (+0.05)
GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 13.77 (+0.12)
Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companies
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c5sqxq/obesity) has announced the addition of the "Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Obesity Overview - Therapeutics Development - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development - Obesity - Therapeutics Assessment - Drug Profiles - Obesity - Recent Pipeline Updates - Obesity - Dormant Projects - Obesity - Discontinued Products - Obesity - Product Development Milestones - Appendix Companies Mentioned - Advinus Therapeutics Ltd. - Amgen Inc. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Galenea Corp. - Genfit SA - GlaxoSmithKline plc - GTx, Inc. - Handok Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Helsinn Healthcare S.A. - High Point Pharmaceuticals, LLC - Insusense Therapeutics ApS - Intarcia Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Kainos Medicine, Inc. - Kissei Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - LG Life Sciences, Ltd. - Mitsubishi Tanabe Pharma Corporation - Molecular Design International, Inc. - Neothetics, Inc. - P2D Bioscience - Pfizer Inc. - PharmaIN Corporation For more information visit http://www.researchandmarkets.com/research/c5sqxq/obesity
JNJ: 99.53 (+1.13), GTXI: 1.37 (+0.01), ESPR: 90.01 (+1.32), ISIS: 53.50 (+0.42), PFE: 34.36 (+0.50), NEOT: 9.91 (+0.68), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Pipeline Review 2015 - 10 Drug Profiles & 16 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mh4n22/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - RegeneRx Biopharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teijin Pharma Limited Drug Profiles - cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - Monoclonal Antibody for CIDP - NNZ-2591 - NP-1998 - NRP-2945 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides for Neuropathic Pain and Peripheral Neuropathy - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/mh4n22/peripheral
INSY: 37.53 (+0.49), PFE: 34.36 (+0.50), ACOR: 34.07 (+0.65)
Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
PRWeb - Tue Feb 10, 7:31AM CST
The report "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-n...eport.html .
PFE: 34.36 (+0.50)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 49.93 (+0.74), MDT: 74.37 (+1.28), LXRX: 8.21 (-0.10), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), ECTE: 1.71 (+0.13), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.92 (unch), APRI: 1.76 (+0.01)
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 61.38 (-0.75), ITCI: 34.76 (+1.70), BCLI: 3.46 (-0.03), OMER: 17.33 (+0.29), NVS: 103.22 (+3.20)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), MRK: 57.95 (+0.57), CGEN: 6.63 (+0.06), PTN: 0.92 (unch), TEVA: 61.38 (-0.75), NVS: 103.22 (+3.20)
